A Fennec Pharmaceuticals drug that prevents hearing loss in children receiving cancer treatment is now approved. The regulatory decision comes more than two years later than expected, but the company now claims its drug, Pedmark, is the first and only FDA-approved therapy for reducing the risk of chemotherapy-induced hearing loss in pediatric cancer patients.
